Sign in

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

@brookmans76.bsky.social
776 followers 574 following 55 posts

Professor of Urology - Urologic Oncology, Sports Medicine @LMU Munich Senior VP Therapeutic Area Head Urologic Oncology, Aura Biosciences, Boston, MA (former J&J R&D) Avid Reader, Hiker, Skier, Enthusiastic Cyclist 🚴‍♀️🚴‍♀️🚴‍♀️ and Wine Grower in Mallorca 🍇🍷

PostsRepliesMedia
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 20/06/2025
Excellent Review on PSMA PET for Prostate Cancer Diagnosis - Sabine D. Brookman-May @brookmans76.bsky.social oncodaily.com/science/psma... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PSMAPET #ProstateCancer
oncodaily.com
Sabine D. Brookman-May: Excellent Review on PSMA PET for Prostate Cancer Diagnosis - OncoDaily
Sabine D. Brookman-May: Excellent Review on PSMA PET for Prostate Cancer Diagnosis / cancer, european urology, OncoDaily, Oncology, prostate cancer, PSMA,
061
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 23/03/2025
Highlights from EAU25 by Sabine Brookman-May @brookmans76.bsky.social @uroweb.bsky.social oncodaily.com/blog/eau25-2... #Cancer #CancerResearch #Medicine #Health #Urology #EAU25 #CancerCongress #Oncology #OncoDaily
oncodaily.com
Highlights from EAU25 by Sabine Brookman-May - OncoDaily
Highlights from EAU25 by Sabine Brookman-May / 40th Annual EAU Congress, bladder cancer, cancer, EAU2025, EAU25, European Association of Urology, Evanguelos
0101
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 22/03/2025
What is the best strategy in BCG unresponsive HR NMIBC? - Sabine D. Brookman-May @brookmans76.bsky.social oncodaily.com/blog/sabine-... #Cancer #CancerResearch #BladderCancer #CancerTreatment #Urology #Medicine #Health #Oncology #OncoDaily
oncodaily.com
Sabine D. Brookman-May: What is the best strategy in BCG unresponsive HR NMIBC? - OncoDaily
Sabine D. Brookman-May: What is the best strategy in BCG unresponsive HR NMIBC? / Ashish M. Kamat, cancer, Carme Mir, OncoDaily, Oncology, Sabine D.
0101
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 13/03/2025
Some contrast to my usual oncology research work - but with a good focus on my #urology background. Talked to @gqmagazine.bsky.social Germany and GoSping.de about #STI #SexuallyTransmittedDiseases and how important #awareness and #treatment is. Great interview! 👉 www.gq-magazin.de/artikel/6-my...
161
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/02/2025
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
0123
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/02/2025
Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer ✅ PFS & OS benefit in all groups ✅ Benefit in cisplatin eligible/ineligible ✅ Safety consistent with prior analysis ✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
051
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 03/02/2025
Great weekend with a 12 1/3 hrs indoor cycling race 🚴‍♂️🚴‍♀️🚴🚴 Great start into the 2025 season and after recovering from 2024 pelvic fracture
130
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 25/01/2025
Just a beautiful weekend! As it should be…
171
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/01/2025
Now published: This MA is the basis for our ongoing #ZMoveMent1 study evaluating the impact of endurance*resistance training on QoL, oncological outcomes, fitness in #ProstateCancee pts 👉 we still don’t use #PhysicalExercise in cancer pts in an optimal way 👉 www.mdpi.com/2072-6694/16...
mdpi.com
The Effect of Resistance and/or Aerobic Training on Quality of Life, Fitness, and Body Composition in Prostate Cancer Patients—A Systematic Review and Meta-Analysis
Background: Prostate cancer (PC) and its treatment are often associated with side effects such as fatigue, muscle loss, and diminished quality of life (QoL). Physical exercise, particularly resistance...
001
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 12/01/2025
Rethinking #ProstateBiopsy protocols: A systematic review (23 studies, 12,324 pts) shows that #AntibioticProhylaxis can safely be omitted in transperineal bx 💉w/o elevating infectious risks 🧫 #ProstateCancer #Urology #AntibioticStewardship @lucacindolo.bsky.social 👉 www.nature.com/articles/s41...
1105
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 11/01/2025
FDA Released Draft Guidance on Incorporating Tissue Biopsies in Clinical Trials @fda.gov oncodaily.com/insight/fda2... #Cancer #FDA #OncoDaily #Oncology #TissueBiopsy #Medicine #Health
oncodaily.com
FDA Released Draft Guidance on Incorporating Tissue Biopsies in Clinical Trials - OncoDaily
FDA Released Draft Guidance on Incorporating Tissue Biopsies in Clinical Trials / cancer, FDA, OncoDaily, Oncology, Richard Pazdur, tissue biopsy
1125
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 11/01/2025
#CREST trial with positive results for #PD-1 in HR #NMIBC! ✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC. ✅The study met its primary endpoint with significant improvement of EFS pfizer.com/news/press-rel… @oncodaily.bsky.social
pfizer.com
153
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 10/01/2025
Alcohol and Cancer Risk: The U.S. Surgeon General’s Advisory 2025 oncodaily.com/insight/218765 #AlcoholAndCancerRisk #Cancer #OncoDaily #Oncology #SurgeonGeneral’sAdvisory #Medicine #Health
oncodaily.com
Alcohol and Cancer Risk: The U.S. Surgeon General’s Advisory 2025 - OncoDaily
Alcohol and Cancer Risk: The U.S. Surgeon General’s Advisory 2025 / Alcohol and Cancer Risk, cancer, OncoDaily, Oncology, Surgeon General’s Advisory
0121
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Juan Luis Vásquez @jlvasquez82.bsky.social · 10/01/2025
Understanding emotions to enhance leadership 💡❤️‍🔥 @brookmans76.bsky.social led a powerful session on Emotional Intelligence — exploring how self-awareness, empathy, and human connection 🤝 can shape better leaders in healthcare 🌟. #EAUTalentIncubator
042
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Juan Luis Vásquez @jlvasquez82.bsky.social · 09/01/2025
Moving from the dance floor 🕺💃 to the balcony 🏛️” - Great leadership requires both action & reflection. Insightful session by @brookmans76.bsky.social at #EAUTalentIncubator on finding balance in leadership! 👏✨ @uroweb.bsky.social #LeadershipDevelopment
012
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/01/2025
New meta-analysis shows #PDE5 inhibitors, like tadalafil & sildenafil, may modestly reduce HbA1c levels in diabetes, with long-acting inhibitors having a greater impact. Promising dual benefit for managing diabetes & #erectiledysfunction. #Diabetes #PDE5 #HbA1c
198
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Yüksel Ürün @yukselurun.bsky.social · 30/12/2024
Immunotherapy shows sex bias—men respond better; women face more severe AEs. Understanding sex hormones, chromosomes, and epigenetics in immunity could lead to tailored immuno-oncology strategies. #Cancer #Immunotherapy #Oncology @oncoalert.bsky.social rdcu.be/d49Mq
0259
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
OncoDaily @oncodaily.bsky.social · 23/12/2024
Gevorg Tamamyan’s first message as New POEM President @gevorgtamamyan.bsky.social oncodaily.com/blog/gevorg-... #Cancer #OncoDaily #Oncology #PediatricCancer #Medicine #PediatricCancerCare #PediatricOncology #Health #EastAndMediterraneanGroup #POEMGroup
oncodaily.com
Gevorg Tamamyan's first message as New POEM President - OncoDaily
Gevorg Tamamyan's first message as New POEM President / cancer, Gevorg Tamamyan, OncoDaily, Oncology, Pediatric cancer, pediatric cancer care, Pediatric
0102
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 23/12/2024
Exercise improves quality of life for #ProstateCancer patients. Our latest systematic review shows combined resistance and aerobic training reduces fatigue, enhances mental and sexual health, and boosts fitness. Resistance training also improves body composition #ProstateCancer #PhysicalExercise
1121
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 21/12/2024
Feels good to realize I am back on @gozwift.bsky.social @zwiftrides.bsky.social to get up to 4 jerseys in one training. Rehab is now definitely over after my pelvic fracture 3 months ago #Roadbike #Cycling Back to real training and rides!
2171
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Yüksel Ürün @yukselurun.bsky.social · 19/12/2024
Genomic sequencing identified hereditary cancer risks in 9% of patients after uninformative gene panels. However, most findings lacked evidence-based guidelines. #Genomics #Cancer #Oncology @oncoalert.bsky.social @viveksubbiah.bsky.social @realbowtiedoc.bsky.social doi.org/10.1200/PO-2...
0169
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 13/12/2024
Also sharing the link to donation in memory and honor of Dr. Felix Feng here: ow.ly/Uc3H50TSBiC
ow.ly
I just helped save a life
You can save one, too. Donate now.
041
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 13/12/2024
It is such bad news - and an incredible loss. Felix Feng has been such a wonderful research partner. I will miss him and the great collaboration we had.
060
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 08/12/2024
#Nectin4 in GU vs other malignancies ✅ Nectin4 is more prevalent in GU cancers than others ✅ still more data needed on the prognostic and predictive value 👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer
071
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Scott Hamilton @sdhamiltonvic.bsky.social · 07/12/2024
Choose 20 books that have stayed with you or influenced you. One book per day for 20 days, in no particular order. No explanations, no reviews, just covers. #booksky 📚💙 #bookchallenge #20daybookchallenge 11/20
1121
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/12/2024
Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS) ✅ 6 & 12 mo CR: 94% & 81% ✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76% ✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social
095
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Matt Cooperberg @dr-coops.bsky.social · 05/12/2024
Great updates from Patrick Hensley and Mark Tyson on the huge and growing array of options for non-muscle-invasive #bladdercancer #SUO24
091
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/12/2024
Great talk indeed @joshmeeks.bsky.social and a very important aspect to be considered for future trials
061
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 05/12/2024
Thank you @oncodaily.bsky.social Great honor to be on your list!
130
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
The OncoAlert Network 🚨 @oncoalert.bsky.social · 02/12/2024
Frailty in older adults w/ #ProstateCancer is a significant challenge, as it can affect both the prognosis and treatment decisions. Frailty results from aging-related declines in physiological reserves and exacerbated by both ADT & the cancer itself, leading to sarcopenia & reduced bone density
061
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 30/11/2024
He was and is an icon and legend #VirgilAbloh Thank you @oncodaily.bsky.social for remembering him I can also recommend reading his Abloh-isms
020
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Yüksel Ürün @yukselurun.bsky.social · 27/11/2024
Life expectancy gaps in the US 🇺🇸 have widened—now over 20 years between groups. Geography, race, & income remain key drivers. 🌍 Globally, disparities may be even worse. Inequities demand urgent action. #HealthDisparities #Longevity #EquityInHealth @oncoalert.bsky.social @ptarantinomd.bsky.social
0114
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 27/11/2024
AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment Some questions remain to be answered related to: ▶️ Heterogeneity of disease ▶️ Interreader variability of pathology assessment ▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social
095
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 26/11/2024
Interesting paper showing that #antibiotics may reduce cancer risk by depleting gut microbiota metabolizing nitrosamines #BladderCancer #Microbiome But (not discussed in the paper): 🚩AB can also disrupt beneficial microbial functions 🚩Increase cancer risk 🚩Negatively impact outcomes of IO therapy
050
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Gil Morgan MD @weoncologists.bsky.social · 26/11/2024
Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨
0167
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 26/11/2024
She has 👉 @loebstacy.bsky.social
030
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 26/11/2024
Great tool! Thank you @bsky.app @rose.bsky.team + independent developer of the searchable starter packs
010
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Yüksel Ürün @yukselurun.bsky.social · 24/11/2024
Early detection of RCC faces unique challenges. As one of the lowest-shedding tumors with few recurrent mutations, genomic approaches remain limited. Novel cfDNA methylation profiling shows promise for non-invasive diagnosis, offering potential breakthroughs in precision medicine. #Oncology
081
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Juan Luis Vásquez @jlvasquez82.bsky.social · 23/11/2024
Another successful module! Thank you so much for your contribution and constant support! ❤️
011
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 23/11/2024
EAU Talent Incubator Module 4 in Berlin was a great one again! Active participants, great topics #Policy #Innovation important for academic and non-academic urologists, and perfect network opportunity @uroweb.bsky.social @jlvasquez82.bsky.social
2112
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
GU Cast | Declan Murphy & Renu Eapen @gu-cast.bsky.social · 23/11/2024
Declan Murphy discusses fast track queues at the Pearly Gates and doublet vs triplet therpy for mHSPC! Teaser for current GU Cast PROSPECT Part 2 #urology #podcast #prostatecancer
173
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Urology On Air @urology-on-air.bsky.social · 19/11/2024
More information about Urology On Air coming soon... www.youtube.com/watch?v=XlVT...
youtube.com
Urology on Air coming soon
YouTube video by hub.
012
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 21/11/2024
Thank you for sharing @dunnedeirdre.bsky.social A great reminder to read this excellent paper
030
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Yüksel Ürün @yukselurun.bsky.social · 20/11/2024
RADICALS-HD: Adding ADT to postop RT in prostate cancer shows no MFS improvement. Long-term outcomes remain favorable, even without ADT. High-risk cases need focus! @oncoalert.bsky.social DOI: 10.1016/j.eururo.2024.07.026
2154
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024
Just out: Our multicenter study comparing Uromonitor® DNA assay to #UrineCytology for #BladderCancer ✅ TERT & FGFR-3 mutations strongly predict UCB ❌ 93.3% specificity, but 49.3% sensitivity only ❌ KRAS mutations lacked predictive value. 🤔 The quest for optimal non-invasive #biomarker continues
030
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024
Please count me in. Besides pelvic floor was never my primary focus as urologist/oncologist, I developed a few years ago the first digital healthcare app for pelvic floor training for men after #ProstateCancer treatment 👉 Pelvintense. www.pelvintense.de (Android). Study results to be presented soon!
pelvintense.de
Profitieren Sie von einem effektiven Trainingsprogramm, das Sie einfach in Ihren Alltag integrieren können.
321
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024
Just in @bjuijournal.bsky.social: Our #TITAN post hoc analysis: Patients with ultralow 0.2 #PSA derived greatest benefit. Less pronounced addtl. benefit for .02 #mHSPC #ProstateCancer 👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social
0148
Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 19/11/2024
Sunrise 2 was recently stopped based on the IDMC recommendation as TAR-200 + Cetrelimab didn't show superiority over chemoradiation. But SR4 still ongoing. And T0 rates (also of other treatments) raise the hope for potential #bladdersparing approaches! #TAR200 #MIBC
141
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 19/11/2024
Great idea to look for most important recent #BladderCancer papers. There is a lot going in both the advanced and also in the localized disease setting right now #NMIBC #MIBC indicating a potential also for bladder-sparing approaches
040
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 18/11/2024
Coming back from Boston last Friday still with crutches due to my #Roadbike accident + pelvic fracture, I decided to get rid of them now and start getting my fitness back on @gozwift.bsky.social @gozwift.bsky.social 7 weeks of muscle and power loss are enough💪🚴‍♀️🚴‍♀️🚴‍♀️
280